Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development of LCP-Tacro for the prevention of organ rejection in kidney transplant patients.
May 30, 2013
Veloxis Pharmaceuticals A/S — annulment of warrants and registration of new Articles of Association pursuant thereto
May 20, 2013
Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors
May 15, 2013
Veloxis Pharmaceuticals announces financial results for the first three months of 2013